Skip to Content

Buspirone Pregnancy and Breastfeeding Warnings

Buspirone is also known as: BuSpar, Vanspar

Buspirone Pregnancy Warnings

This drug should be used during pregnancy only if clearly needed. AU TGA pregnancy category: B1 US FDA pregnancy category: B

Animal studies have not revealed any fetal damage or fertility impairment. There are no controlled data in human pregnancy. AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Buspirone Breastfeeding Warnings

An exclusively breastfed 11-week-old infant whose mother took 10 mg of this drug and 300 mg of venlafaxine daily showed no adverse reactions.

This drug should not be used during breastfeeding unless clinically necessary. Excreted into human milk: Yes Comments: -Limited information indicates maternal doses up to 45 mg daily of this drug produce low levels in milk. -This drug increases serum prolactin; however, the prolactin level in a mother with established lactation may not affect her ability to breastfeed. -There is no information available on the long-term use of this drug during breastfeeding.

See references

References for pregnancy information

  1. "Product Information. Buspar (buspirone)." Bristol-Myers Squibb, Princeton, NJ.

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Buspar (buspirone)." Bristol-Myers Squibb, Princeton, NJ.
  4. Cerner Multum, Inc. "Australian Product Information." O 0

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.